Clover Health Triumphs in Court – Massive 4.5-Star Medicare Rating Upgrade
Clover Health got its Medicare rating raised to 4.5 stars, boosting future government bonus payments from 2027.
/ 495 items
#XY Event-Driven Stocks↓
Sanofi’s Phase 3 CIDP Failure Hits Riliprubart and Raises Doubts for Dianthus’ Claseprubart
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Cellectis Receives FDA RMAT Status for lasme-cel – First Allogeneic CAR-T in Pivotal Trial for r/r B-ALL
Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.
Perrigo CEO Resigns Over Personal Conduct – Interim Leader Named
Perrigo CEO resigned over conduct issues; interim CEO Albert Manzone appointed; company keeps 2026 sales and earnings targets unchanged.
FDA Greenlights Alterity’s Phase 3 Plan for ATH434 in Multiple System Atrophy
Alterity’s drug ATH434 slowed MSA progression in trials, and FDA-approved Phase 3 plans bring it closer to becoming the first real treatment.
Novanta Buys Riverpoint Medical for Up to $1.45B to Boost Minimally Invasive Surgery Portfolio
Novanta to buy Riverpoint Medical for up to $1.45B, doubling its recurring medical consumables revenue and expanding into minimally invasive surgical devices. Deal expected to close Q3 2026.